Increased Serum Levels of Interleukin-6, Immunoglobulin and Acute Phase Protein in Patients with the Severe Clinical Form of Inherited Epidermolysis Bullosa-Reference-Cited by-同舟云学术

Increased Serum Levels of Interleukin-6, Immunoglobulin and Acute Phase Protein in Patients with the Severe Clinical Form of Inherited Epidermolysis Bullosa

Published:2005-06 Issue:6 Volume:32 Page:503-505
ISSN:0385-2407
Container-title:The Journal of Dermatology
language:en
Short-container-title:The Journal of Dermatology

Author:

Kawakami Yoshio¹,Oyama Noritaka¹,Ohtsuka Mikio¹,Nakamura Koichiro¹,Kaneko Fumio¹

Affiliation:

1. Department of Dermatology; Fukushima Medical University Graduate School of Medicine; Fukushima Japan

Publisher

Wiley

Subject

Dermatology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1346-8138.2005.tb00790.x/fullpdf

Reference13 articles.

1. Sybert VP Genetic skin disorder Oxford 129 162 1997

2. Multicentric Castleman's disease associated with inherited epidermolysis bullosa;Kawakami;J Dermatol,2003

3. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy;Nishimoto;Blood,2000

4. Interleukin-6 family of cytokines and gp130;Kishimoto;Blood,1995

5. Interleukin-6 is pyogenic but not somnogenic;Opp;Physiol Behav,1989

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Successful treatment of multicentric Castleman's disease associated with dystrophic epidermolysis bullosa using anti‐interleukin‐6 receptor antibody;The Journal of Dermatology;2024-03-14

2. Elevated expression of interleukin‐6 (IL‐6) and serum amyloid A (SAA) in the skin and the serum of recessive dystrophic epidermolysis bullosa: Skin as a possible source of IL‐6 through Toll‐like receptor ligands and SAA;Experimental Dermatology;2024-03

3. Efficacy of oral JAK1 or JAK1/2 inhibitor for treating refractory pruritus in dystrophic epidermolysis bullosa: A retrospective case series;The Journal of Dermatology;2023-12-20

4. Detrimental Effects of IFN-γ on an Epidermolysis Bullosa Simplex Cell Model and Protection by a Humanized Anti–IFN-γ Monoclonal Antibody;JID Innovations;2022-03

5. New insight of itch mediators and proinflammatory cytokines in epidermolysis bullosa;Journal of Cutaneous Immunology and Allergy;2022-02-07